ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Tamoxifen

Also written as “tamoxifen”, “Tamoxifen (Nolvadex)” and “TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen”.

Its studies are mostly in Breast Neoplasms · Neoplasms · Ovarian Neoplasms, led by 6 companies.

Drug pageTamoxifen: every studyMany companies study it; this page follows only the 14 they lead. All 207 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 30, 200514 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only80 open or runningphase 3since Sep 30, 2005Sep 30, 2005none ahead
Pfizerits history only20 open or runningphase 4since Aug 25, 2010May 8, 2002none ahead
Changchun GeneScience Pharmaceutical11 open or runningphase 3since May 31, 2024May 31, 2024none ahead
Daré Bioscienceits history only10 open or runningphase 2since May 2, 2022May 2, 2022none ahead
Mediclinic Middle Eastits history only10 open or runningphase 2since Mar 14, 2019Mar 14, 2019none ahead
Nalagenetics Pteits history only10 open or runningno phasesince Aug 12, 2022Aug 12, 2022none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Changchun GeneScience Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 31, 2024First study: phase 3 study in Breast Cancer SubjectsFirst studyNCT06449027 · 211 enrolled · China

TargetBeta

ESR1 →read by rule
“Estrogen receptor alpha modulator”ChEMBL 37, by rule

Other programs on ESR1

ProgramCompanyFurthest phaseStudies
Ethinyl EstradiolruleJohnson & Johnsonphase 470
EstradiolruleNovo Nordiskphase 469
FulvestrantruleAstraZenecaphase 430
ClomipheneruleHamad Medicalphase 43
vepdegestrantrulePfizerphase 320
camizestrantruleAstraZenecaphase 318
giredestrantHoffmann-La Rochephase 317
HRS-8080Jiangsu HengRui Medicinephase 313
elacestrantruleMenarini Groupphase 312
ImlunestrantruleEli Lillyphase 312
taragarestrantruleInventisBiophase 35
SIM0270ruleSimcere Pharmaceutical Groupphase 35

Studies

The one study Changchun GeneScience Pharmaceutical leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06449027Breast Cancer Subjects · China3Active, not recruitingNov 2025211

How it is read

Names in the registry

  • “Tamoxifen”, 11 entries
  • “tamoxifen”, 2 entries
  • “Tamoxifen (Nolvadex)”, 2 entries
  • “TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen”, 1 entry
  • “T Leuprolide Injectable Emulsion”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.